Jiahui Cancer Center Treats First International Patient with Solid Tumor CAR-T Therapy
Jiahui International Cancer Center in Shanghai has begun treating the world's first international patient with Satri-cel, a newly approved CAR-T therapy for solid tumors. This marks a milestone in expanding global access to the treatment.
Jiahui International Cancer Center (JICC) in Shanghai has commenced treatment for the world's first international patient utilizing Satri-cel, a CAR-T therapy recently approved for solid tumors. This event signifies a significant step in making advanced cancer treatments accessible globally.
The therapy, Satri-cel, has secured approval for treating solid tumors, a crucial development for CAR-T technology which has historically been applied primarily to blood cancers. This expansion offers new hope for patients with advanced or refractory solid tumor diagnoses.
According to JICC, the treatment began in early July. The center has not disclosed the patient's nationality or specific cancer type.
The initiation of this treatment for an international patient at JICC highlights the center's commitment to providing specialized cancer care to a global patient base. This move could pave the way for wider international adoption and accessibility of cutting-edge oncological therapies.